Canagliflozin shows benefit in T2D and CKD, even without CVD

  • Mahaffey KW & al.
  • Circulation
  • 11 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In participants with type 2 diabetes (T2D) and chronic kidney disease (CKD), canagliflozin reduces major cardiovascular events and renal outcomes with or without baseline cardiovascular disease (CVD).

Why this matters

  • Effects of sodium glucose co-transporter 2 inhibitors are uncertain in people without prior CVD.

Study design

  • In CREDENCE, 4401 participants with T2D (49.6% primary prevention) and CKD (estimated glomerular filtration rate 30 to 2 and albumin:creatinine >300-5000 mg/g) were randomly assigned to canagliflozin or placebo (+optimized standard of care), mean follow-up 2.62 years.
  • Funding: Janssen Research & Development, LLC.

Key results

  • Compared with placebo, canagliflozin reduced overall risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke:
    • 9.9% vs 12.2%;
    • HR, 0.80 (P=.01);
    • Similar results for the individual components.
  • Effects were consistent for primary and secondary prevention groups, respectively:
    • HR, 0.68 (95% CI, 0.49-0.94); and
    • HR, 0.85 (0.69-1.06; P-interaction=.25).
  • Canagliflozin reduced renal outcomes overall (HR, 0.66; P<.001 and similarly in primary secondary prevention groups p-interaction values>
  • No difference from placebo in overall risk of fracture (HR, 0.98; 95% CI, 0.70-1.37) or amputations (1.11; 0.79-1.56), with similar findings in primary and secondary prevention groups.

Limitations

  • Low statistical power for some subgroups.
  • No formal CVD assessment.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit